Table 2.

Number of MIS-C cases, estimated SARS-CoV-2 infections, and incidence of MIS-C after SARS-CoV-2 infections in children and adolescents in Denmark by age group, vaccination status, and SARS-CoV-2 variant

	Wildtype (March, 2020, to February, 2021*)				Delta (August, 2021, to February, 2022)
	MIS-C (n)	Estimated SARS-CoV-2 infections† (n)	Incidence of MIS-C per 1 000 000 infected children and adolescents (95% CI)	Incidence of MIS-C in infected children and adolescents	MIS-C (n)	Estimated SARS-CoV-2 infections‡ (n)	Incidence of MIS-C per 1 000 000 infected children and adolescents (95% CI)	Incidence of MIS-C in infected children and adolescents
Not vaccinated
Total	23	93 397	246 (156–369)	1 in 4100 (2700–6400)	51	175 458	291 (216–382)	1 in 3400 (2600–4600)
0–4 years	4	24 939	160 (44–411)	1 in 6200 (2400–22 700)	3	61 573	49 (10–142)	1 in 20 500 (7000–100 000)
5–11 years	10	35 762	280 (134–514)	1 in 3600 (1900–7500)	42	88 295	476 (343–643)	1 in 2100 (1600–2900)
12–17 years	9	33 183	273 (125–519)	1 in 3700 (2700–6400)	6	25 590	234 (86–510)	1 in 4300 (2000–11 600)
Vaccinated§
12–17 years	..	..	..	..	1	9855	101 (3–565)	1 in 9900 (1800–390 000)

MIS-C=multisystem inflammatory syndrome in children.

^*Data regarding incidence of MIS-C after the wildtype strain has been published previously.³

^†Estimated by serology.³

^‡Estimated cases of SARS-CoV-2 in the period July 15 to Dec 15, 2021 (using a multiplier of 1·5 to laboratory conformed cases in individuals 5–17 years and 6·1 in individuals 0–4 years).

^§Defined as SARS-CoV-2 infection occurring at least 14 days after the second vaccine dose.